Bright Minds Biosciences
DRUG
7 hedge funds and large institutions have $256K invested in Bright Minds Biosciences in 2024 Q1 according to their latest regulatory filings, with 3 funds opening new positions, 1 increasing their positions, 1 reducing their positions, and 4 closing their positions.
0% more repeat investments, than reductions
Existing positions increased: 1 | Existing positions reduced: 1
1.62% less ownership
Funds ownership: 6.56% → 4.94% (-1.6%)
13% less funds holding
Funds holding: 8 → 7 (-1)
23% less capital invested
Capital invested by funds: $330K → $256K (-$74.2K)
25% less first-time investments, than exits
New positions opened: 3 | Existing positions closed: 4
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Citadel Advisors
Miami,
Florida
|
+$31.3K |
| 2 |
Jane Street
New York
|
+$24.2K |
| 3 |
National Bank of Canada
Montreal,
Quebec, Canada
|
+$8.76K |
| 4 |
Royal Bank of Canada
Toronto,
Ontario, Canada
|
+$585 |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
HF
HRT Financial
New York
|
-$24K |
| 2 |
AI
AdvisorShares Investments
Bethesda,
Maryland
|
-$21.2K |
| 3 |
Renaissance Technologies
New York
|
-$17K |
| 4 |
VF
Virtu Financial
New York
|
-$15K |
| 5 |
UBS Group
Zurich,
Switzerland
|
-$889 |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
AI
1
AdvisorShares Investments
Bethesda,
Maryland
| $211K | -$21.2K | -12,081 | -6% |
|
|
2
Citadel Advisors
Miami,
Florida
| $21.4K | +$31.3K | +17,829 | New |
|
|
3
Jane Street
New York
| $16.6K | +$24.2K | +13,795 | New |
|
|
4
National Bank of Canada
Montreal,
Quebec, Canada
| $5.25K | +$8.76K | +5,000 | New |
|
|
5
Royal Bank of Canada
Toronto,
Ontario, Canada
| $1K | +$585 | +334 | +120% |
|
|
APC
6
Aspire Private Capital
Cornelius,
North Carolina
| $120 | – | – | – |
|
7
BlackRock
New York
| $1 | – | – | – |
|
|
HF
8
HRT Financial
New York
| – | -$24K | -16,845 | Closed |
|
|
9
Renaissance Technologies
New York
| – | -$17K | -11,996 | Closed |
|
|
VF
10
Virtu Financial
New York
| – | -$15K | -10,399 | Closed |
|
|
11
UBS Group
Zurich,
Switzerland
| – | -$889 | -622 | Closed |
|
DRUG Hedge Fund Activity: Q1 2024 in Review
7 of the 6,942 institutional investors tracked by Wall St. Rank reported a position in Bright Minds Biosciences (DRUG) for Q1 2024, worth a combined $256K — down 23% from $330K a quarter earlier.
Sellers outnumbered buyers: 4 funds closed out of DRUG and 3 opened new positions — a net loss of 1 holder — while 1 trimmed existing stakes and 1 added.
The largest buyer was Citadel Advisors, opening a new position worth an estimated $31.3K. The largest seller was HRT Financial, exiting entirely with an estimated $24K sold.
- 7 institutional investors held Bright Minds Biosciences (DRUG) as of Q1 2024, down from 8 in Q4 2023.
- Funds reported $256K of Bright Minds Biosciences stock for Q1 2024, down 23% quarter-over-quarter.
- 3 funds opened new Bright Minds Biosciences positions in Q1 2024 and 4 closed out, a net change of -1 holder.
- The largest Bright Minds Biosciences buyer in Q1 2024 was Citadel Advisors, an estimated $31.3K added.
- The largest Bright Minds Biosciences seller in Q1 2024 was HRT Financial, an estimated $24K sold.
Based on aggregated 13F filings for Q1 2024.